atx-gd-59
Peptideexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02973802)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Thyroid stimulating hormone receptorSupplementation
TSHR supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- atx-gd-59
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02973802 | Phase 1 | Sep 1, 2016 | Apitope, European Commission, IQVIA, University of Melbourne |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apitope | For profit | 1 | 1 | 1 | 2016 |
| European Commission | Government | 1 | 0 | 1 | 2016 |
| IQVIA | For profit | 1 | 0 | 1 | 2016 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1